Newsflash: The Dividend Aristocrats Found The Lost Decade
There are many people who continue to hold a jaundiced view of stocks because they were traumatized by the last two recessions.
Read more »|
Price
$3.39
|
Market Cap
14.8M
|
Sector
Health Care
|
Div. Growth
-
|
|
P/E
29.1
|
P/B
0.78
|
P/S
0.7
|
Dividend %
-
|
|
P/CF
-
|
P/FCF
2.5
|
Op. Cash Flow
-
|
FCF/Share
1.2
|
|
Op. Margin
7.20%
|
Net Margin
2.30%
|
ROE
2.50%
|
ROI
2.40%
|
|
ROA
0.80%
|
EPS Growth
900.00%
|
Curr. Ratio
2.0
|
Debt/Equity
161.7
|
| Company | Price | P/E | Div. Yield | Market Cap ($Mil) | Rating |
|---|---|---|---|---|---|
| Urologix, Inc. (ULGX) | $1.02 | - | - | 16M | |
| IVAX Diagnostics, Inc. (IVD) | $0.62 | - | - | 24.4M | |
| ISTA Pharmaceuticals, Inc. (ISTA) | $9.07 | - | - | 379.2M | |
| Invacare Corporation (IVC) | $14.60 | - | 0.30% | 504.3M | |
| Integrated BioPharma, Inc. (INBP) | $0.08 | - | - | 1.1M |
There are many people who continue to hold a jaundiced view of stocks because they were traumatized by the last two recessions.
Read more »I'm inspired to write this article because I am so frustrated by the plethora of all the so-called expert market prognosticators that continuously bombard the public with negative forecasts.
Read more »One of the great long-term benefits that a recession brings is the opportunity to invest in extremely high-quality companies at low valuations.
Read more »Please note that all recommendations are based on our model's results and do not represent our personal opinion. The stock Rating process is purely mechanical.
All analysis relies on publicly available financial information. Learn More
All articles will be reviewed prior to publishing. You will be notified by email if we choose to publish your article.
×